Traders should monitor upcoming catalysts including completion of MAVERIC trial enrollment in Q2 2026 and potential topline data readout thereafter, as well as further clinical developments for CRD-38. The strong clinical data, expanded IP, and secured funding reduce near-term dilution risk and increase the likelihood of regulatory and commercial milestones, potentially re-rating the stock ahead of data readouts.
Price Chart
Executive Summary
Cardiol Therapeutics announced positive clinical progress across its pipeline, including advancement of its Phase III MAVERIC trial in recurrent pericarditis with over 50% enrollment completed, positive Phase II ARCHER data showing significant cardiac structural improvement in acute myocarditis, advancement of its next-generation CRD-38 program toward IND submission, a U.S. patent allowance extending protection to 2040, and a $31 million capital raise providing cash runway into Q4 2027. These developments strengthen the company's clinical, intellectual property, and financial position ahead of key value-inflection milestones.
Key Facts
- Initiated pivotal Phase III MAVERIC trial in recurrent pericarditis and surpassed 50% patient enrollment, with full enrollment expected in Q2 2026
- Reported positive Phase II ARCHER data: CardiolRx significantly reduced left ventricular mass by 9.2g (p=0.0117) in acute myocarditis patients
- ARCHER results published in ESC Heart Failure, a leading European Society of Cardiology journal
- Advanced CRD-38 program to support IND application and initiation of Phase I clinical development
- Received U.S. patent allowance protecting CardiolRx and CRD-38 for multiple cardiac conditions through October 2040
- Strengthened board with election of Dr. Timothy Garnett, former Chief Medical Officer of Eli Lilly
- Raised $31 million in aggregate gross proceeds ($16M in Oct 2025, $14.85M in Jan 2026), providing cash runway into Q4 2027
Financial Impact
$31 million raised, funding runway extended to Q4 2027, with no dilution details provided
Risk Factors
- Clinical trial results may not replicate in larger studies or achieve statistical significance on primary endpoints
- Regulatory approval is not guaranteed even with positive trial data
- Biotech stocks are inherently volatile and sensitive to clinical and funding news
- Market cap remains small ($135M), increasing susceptibility to sentiment swings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001062993-26-001780 |
| Document: form6k.htm | 0001062993-26-001780 |
| Document: 0001062993-26-001780-index-headers.html | 0001062993-26-001780 |
| Document: 0001062993-26-001780-index.html | 0001062993-26-001780 |
| Document: 0001062993-26-001780.txt | 0001062993-26-001780 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | SC 13G/A | $1.77 | awaiting T+60 | — | $1.15 (−35.03%) |
Sep 23, 2026 4w ago | 6-K | $1.77 | awaiting T+60 | — | $1.15 (−35.03%) |
Sep 16, 2026 5w ago | 6-K | $1.90 | awaiting T+60 | — | $1.15 (−39.47%) |
Sep 10, 2026 6w ago | 6-K | $2.00 | awaiting T+60 | — | $1.15 (−42.36%) |
Sep 10, 2026 6w ago | 6-K | $2.00 | awaiting T+60 | — | $1.15 (−42.36%) |
Sep 9, 2026 6w ago | 6-K | $2.29 | awaiting T+60 | — | $1.15 (−49.67%) |
Aug 5, 2026 11w ago | 6-K | $1.34 | awaiting T+60 | — | $1.15 (−14.18%) |
Jul 14, 2026 15w ago | 6-K | $1.15 $1.32 | ▲ +14.78% | ▲ +11.41% | $1.15 (−0.00%) |
Jul 9, 2026 15w ago | 6-K | $0.9920 $1.41 | ▲ +42.14% | ▲ +40.50% | $1.15 (+15.93%) |
May 26, 2026 22w ago | 6-K | $1.30 $1.96 | ▲ +50.77% | ▲ +48.04% | $1.15 (−11.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers